[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lung-transplant-recipient\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lung-transplant-recipient":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,69],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100624490","early-phase-1-bridge---blocking-receptor-of-il-1-for-donor-graft-edema-reduction-100624490",false,"NCT07410312","BRIDGE - Blocking Receptor of IL-1β for Donor Graft Edema Reduction","Inclusion Criteria:\n\n* Age 18 years or older.\n* Planning to undergo transplantation of the lung.\n* Willing and able to read, understand, and be capable of giving informed consent.\n* Use of ex vivo lung perfusion (EVLP) prior to lung transplant.\n\nExclusion Criteria:\n\n* Previous or current use of IL-1R antagonist drug.\n* Any condition that, in the opinion of the attending physician, would place the patient at undue risk by participating, such as highly sensitized patients who require additional immunosuppression, multiorgan transplant, and re- transplant.","ALL","18 Years",{"count":18,"type":19},20,"ESTIMATED","INTERVENTIONAL",[22],"EARLY_PHASE1","This study will determine if primary graft dysfunction (which causes low blood oxygen levels and fluid or inflammation in the lungs) after lung transplant can be prevented through the use of the study drug (IL-1 receptor antagonist, Anakinra). In this study, lung transplant participants who are randomized to the treatment group will have the study drug injected into the solution that their donor lungs are kept in prior to transplant.",[25],"Lung Transplant Recipient",[27],"lung transplant","NOT_YET_RECRUITING","2026-06-24",{"date":31,"type":32},"2026-06-25","ACTUAL",{"date":34,"type":19},"2026-07-01",{"date":36,"type":19},"2027-12",{"name":38,"class":39},"Northwestern University","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":20,"phases":51,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":40},"100611061","phase-4-combination-letermovir-and-standard-of-care-antiviral-for-enhanced-antiviral-response-in-cytomegalovirus-infection-in-lung-transplant-recipients-100611061","NCT07235683","Combination Letermovir and Standard of Care Antiviral for Enhanced Antiviral Response in Cytomegalovirus Infection in Lung Transplant Recipients","Combination Letermovir and Standard of Care Antiviral for Enhanced Antiviral Response in Cytomegalovirus Infection in Lung Transplant Recipients: A Pilot Trial","CLEAR-CMV","Inclusion Criteria:\n\n* Recipient of a lung transplant.\n* Has confirmed CMV viremia with a viral load ≥ 1000 IU\u002FmL and will receive or has just started SOC antiviral treatment in the past 72h as per the decision of the treating physician.\n\nExclusion Criteria:\n\n* Renal failure with Creatinine clearance \\\u003C15 mL\u002Fmin or requiring dialysis\n* Severe hepatic impairment (Child-Pugh Class C)\n* Participating in another interventional clinical trial\n* Combined transplant (e.g heart-lung, lung-liver)\n* Known allergy or contraindication to any of the antiviral medications\n* Known antiviral resistance.\n* Patient receiving cyclosporin, pimozide or ergot alkaloids (due to significant drug interaction with letermovir).\n* Patient receiving or expected to receive CMV immunoglobulin or IVIG during the initial three week treatment phase",{"count":50,"type":19},40,[52],"PHASE4","The primary objective of the CLEAR-CMV trial is to evaluate the efficacy of letermovir therapy plus standard of care (SOC) antiviral compared to SOC plus placebo in achieving clearance of CMV viremia by week 3 in lung transplant recipients with active CMV infection.",[55,25],"CMV",[57,58],"CMV Disease","Lung Transplant","RECRUITING","2026-02-12",{"date":62,"type":32},"2026-02-17",{"date":64,"type":32},"2025-12-24",{"date":66,"type":19},"2027-08",{"name":68,"class":39},"University Health Network, Toronto",{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":20,"phases":78,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":91,"locationsCount":40},"100607501","phase-4-combined-light-exvivo-and-antivirals-for-recipients-of-lungs-from-hbv-donors-100607501","NCT07189377","Combined Light, ExVivo, and Antivirals for Recipients of Lungs From HBV Donors","Lung Transplantation Using Hepatitis B Positive Donors to Hepatitis B Negative Recipients Using Ex-Vivo Treatment of Organs: A Safety Trial","CLEAR-HBV","Donor Inclusion Criteria\n\n* Donor lung suitable for transplantation\n* HBV SAg positive and\u002For HBV NAT+ donor\n\nDonor Exclusion Criteria\n\n* HIV positive\n* HTLV 1\u002F2 positive;\n* Any medical issues in the donor that would normally clinically exclude the donor (e.g. history of cancer, evidence of organ dysfunction, etc).\n\nRecipient inclusion Criteria:\n\n* Recipients eligible and listed for lung transplant\n* HBV NAT negative\n* Provides written informed consent\n* Has received at least 3 prior doses of Hepatitis B vaccine or anti-HBs\\>=10 IU\u002FmL\n* Patients with other co-morbid conditions (such as diabetes, autoimmune disease, renal dysfunction) will remain eligible provided they are otherwise medically suitable for transplantation. The exception to this will be patients with significant liver disease as outlined below.\n\nRecipient exclusion Criteria:\n\n* Chronic liver disease with \\> stage 2 fibrosis\n* Participating in another interventional clinical trial\n* Recipient listed for combined transplant (e.g., heart-lung, lung-liver)\n* Known allergy or contraindication to any of the antiviral medications\n* Hepatitis B surface antigen (HBsAg) or Hepatitis B core Ab positive pre-transplant (indicates already HBV infected).\n* HIV positive\n* Patients with a low level of serum IgA pre-transplant (this may be a risk factor for sensitivity reaction to HBIG).",{"count":18,"type":19},[52],"The aim of the study is to show that transplantation of lungs from Hepatitis B-infected donors is safe when using EVLP with UV light inactivation plus antivirals",[81,25],"Hepatitis B Virus (HBV)",[83,84,27],"HBV Disease","EVLP","2025-11-13",{"date":87,"type":32},"2025-11-17",{"date":89,"type":32},"2025-09-24",{"date":66,"type":19},{"name":68,"class":39}]